VaxInnate Awarded Contract by the U.S. Government To Develop Recombinant Seasonal and Pandemic Flu Vaccines
Potential value of contract as high as $196 million
CRANBURY, NJ, March 1, 2011 – VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines. VaxInnate is a biotechnology firm pioneering breakthrough technology for use in developing novel vaccines.
The contract initially provides funding of $118 million for a base period of 36 months, with an option to extend for 24 months. The contract is effective on February 24, 2011.
“We’re pleased and gratified to receive this award and look forward to working with BARDA to develop the next generation of vaccines for the prevention of seasonal and pandemic flu,” said Thomas Hofstaetter, PhD, President and CEO of VaxInnate. “The contract is an endorsement of Vaxinnate’s proprietary technology, which makes it possible to produce hundreds of millions of doses of safe, effective flu vaccine rapidly and at low cost. It also demonstrates the potential of our technology to meet other critical and emerging public health threats in the future.”
Initial clinical trials will evaluate the components and combinations of what will ultimately be several different pandemic flu vaccines and a seasonal quadravalent flu vaccine, produced using VaxInnate’s proprietary technology. The technology involves genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system.
VaxInnate has already completed a series of Phase I/II trials using VAX 125 and VAX128, prototype vaccines for both seasonal and pandemic Type A1 flu vaccines. The most recent trial assessed the safety and immunogenicity of three different forms of the VAX128 vaccine in several hundred healthy adults aged 18-49 and more than 100 community-living adults ≥ 65 years of age in the United States. VAX128 was demonstrated to be highly immunogenic at low doses (1-2.5 µg) and well tolerated up to 20-µg doses.
Further, the trial confirmed the safety and efficacy of the vaccine forms in elderly subjects, who are less responsive to flu vaccines due to the effects of aging on the immune system. People aged 65 and older, a population segment that is growing rapidly as baby-boomers age, suffer disproportionately from seasonal flu and its complications.
VaxInnate is a privately-held biotechnology company in Cranbury, NJ that is pioneering breakthrough technology for use in developing novel and proprietary vaccines. VaxInnate’s proprietary technology — based upon recombinant fusion molecules that combine the vaccine antigen with a potent immune stimulator, the toll-like receptor 5 (TLR-5) agonist flagellin — conveys significant speed, cost and volume advantages, making it capable of producing hundreds of millions of vaccine doses in just three months.
VaxInnate’s first vaccines focus on infectious diseases, including seasonal and pandemic flu, malaria, dengue and yellow fever. VaxInnate has generated positive Phase I and Phase II clinical data for its first three vaccines, a universal flu vaccine and prototype seasonal and pandemic flu vaccines, the last two of which demonstrated superior efficacy in elderly subjects. For more information about VaxInnate, please visit https://vaxinnate.com.